{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-051121","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.982361+00:00","generated_at":"2026-05-23T21:04:01.675207+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara amends Pierre Fabre deal; transfers manufacturing, reduces milestones; eligible for up to $550M","bullets":["Transferred all manufacturing responsibility for tab-cel to Pierre Fabre as of March 31, 2025; Pierre Fabre will manufacture and supply worldwide at its cost.","Pierre Fabre assumes remediation costs for third-party facility to address FDA requests and support BLA resubmission for tab-cel.","Atara reduced certain potential future regulatory and commercial milestone payments in exchange for the accelerated transfer and cost assumption.","Atara now entitled to aggregate of up to $550M in potential milestones, including up to $40M regulatory milestones for FDA BLA approval; royalties unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-051121","json":"https://secwatch.observer/filing/0000950170-25-051121.json","markdown":"https://secwatch.observer/filing/0000950170-25-051121.md","text":"https://secwatch.observer/filing/0000950170-25-051121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025051121/0000950170-25-051121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025051121/atra-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T21:04:01.675207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}